share_log

LadRx (NASDAQ:CYTR) Coverage Initiated at StockNews.com

kopsource ·  Jan 28, 2023 04:43

StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report published on Tuesday morning. The brokerage issued a hold rating on the stock.

LadRx Stock Performance

LadRx has a 12-month low of $0.05 and a 12-month high of $0.86. The stock's 50 day moving average is $0.09 and its 200-day moving average is $0.12.

Get LadRx alerts:

LadRx Company Profile

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

See Also

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment